Is Lineage Cell Therapeutics Inc (LCTX) a Bad Choice in Biotechnology Tuesday?

Lineage Cell Therapeutics Inc (LCTX) is around the top of the Biotechnology industry according to InvestorsObserver. LCTX received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. Lineage Cell Therapeutics Inc also achieved a score of 74 in the Biotechnology industry, putting it above 74 percent of Biotechnology stocks. Biotechnology is ranked 16 out of the 148 industries.

LCTX has an Overall Score of 62. Find out what this means to you and get the rest of the rankings on LCTX!

See Full LCTX Report

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Lineage Cell Therapeutics Inc Stock Today?

Lineage Cell Therapeutics Inc (LCTX) stock is trading at $1.21 as of 3:17 PM on Tuesday, Mar 19, a gain of $0.04, or 2.99% from the previous closing price of $1.17. The stock has traded between $1.15 and $1.24 so far today. Volume today is below average. So far 338,086 shares have traded compared to average volume of 876,369 shares. Click Here to get the full Stock Report for Lineage Cell Therapeutics Inc stock.